For James Foster, CEO of what is already the second largest Massachusetts-based company in the drug development industry by headcount, Charles River Laboratories, continued growth is a necessity.
That mentality has spurred seven acquisitions since 2014 — a total investment of over $1 billion. This week, the Wilmington-based contract research organization announced an eighth — the acquisition of Woburn’s Blue Stream LaboratoriesInc., which specializes in biosimilars, for an undisclosed price.
